Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00999531
Registration number
NCT00999531
Ethics application status
Date submitted
20/10/2009
Date registered
21/10/2009
Date last updated
10/03/2010
Titles & IDs
Public title
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
Query!
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Volunteers
Query!
Secondary ID [1]
0
0
GS-US-221-0107
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis
0
0
Query!
Mucociliary Clearance
0
0
Query!
Airway Hydration
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Cystic fibrosis
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GS-9411
Treatment: Drugs - Placebo
Experimental: 1 - GS-9411 9.6 mg
Experimental: 2 - GS-9411 4.8 mg
Experimental: 3 - GS-9411 2.4 mg
Placebo Comparator: 4 - Saline Placebo
Treatment: Drugs: GS-9411
Inhaled GS-9411 dissolved in sterile saline
Treatment: Drugs: Placebo
Inhaled Placebo, sterile saline
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability of multiple doses of inhaled GS-9411 in healthy volunteers
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
21 Days
Query!
Secondary outcome [1]
0
0
Assess the pharmacokinetics of GS-9411 and its metabolites
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
21 Days
Query!
Eligibility
Key inclusion criteria
- Males and females, 18 to 65 years of age
- No clinically important abnormal physical findings at Screening
- No clinically relevant abnormalities in the results of laboratory evaluation at
Screening
- Must test negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human
immunodeficiency virus (HIV) at Screening
- Normal electrocardiogram (ECG) at Screening
- Normal blood pressure (BP) and heart rate (HR) in the absence of any medications for
body weight between 50 and 125 kg and within ± 15% of ideal body weight or body mass
index (BMI) between 18 and 28 kg/m2 at Screening
- Able to communicate well with the investigator and to comply with the requirements of
the entire study
- Provision of written informed consent to participate as shown by a signature on the
volunteer consent form
- Nonsmokers of at least 180 days (6 months) duration (< 10 pack/year history) prior to
Screening
- Negative for drugs of abuse (including alcohol) at Screening and Day -5
- Must be willing to abstain from alcohol and strenuous exercise during the 48 hours
prior to Day -5 and during the study
- Forced expiratory volume in 1 second (FEV1) = 80% of predicted normal for age, gender,
and height at Screening and predose
- Normal intraocular pressure (IOP) between 10 and 21 mm Hg at Screening
- Male subjects who are sexually active must be willing to use effective barrier
contraception (e.g., condoms) during heterosexual intercourse from Day -5 through
completion of the study and continuing for at least 90 days from date of last dose of
study drug
- Male subjects must refrain from sperm donation from Day -5 through completion of the
study and continuing for at least 90 days from the date of last dose of study drug
- Non-lactating females. Females on hormone replacement therapy (estrogen/progesterone)
or contraceptive therapy must be stabilized on a product and dose for at least 90 days
prior to Screening
- Females must have a negative serum gonadotropin pregnancy test at Screening and Day -1
- Nonpregnant females of childbearing potential must agree to use highly effective (<1%
failure rate) contraception during heterosexual intercourse from Screening, throughout
the study, and for at least 30 days following the last dose of study drug
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Any prior exposure to GS-9411
- Administration of any investigational drug in the period 84 days (12 weeks) prior to
Screening; 112 days (16 weeks) if the previous investigational drug was a new chemical
entity
- A need for any medication during the period 0 to 5 days prior to Screening, except
those deemed by the principal investigator/clinical investigator not to interfere with
the outcome of the study
- Existence of any surgical or medical condition which, in the judgment of the clinical
investigator, might interfere with the absorption, distribution, metabolism, or
excretion of the drug
- Presence or history of allergy requiring treatment. Hay fever is allowed unless it is
active or has required treatment within 56 days (8 weeks) of Screening
- Donation or loss of greater than 400 mL of blood in the period 84 days (12 weeks)
prior to Screening
- Serious adverse reaction or hypersensitivity to any drug
- Presence or history of any pulmonary diseases (e.g., asthma, emphysema, chronic
bronchitis, CF, bronchiectasis)
- Lactating females
- History of glaucoma
- Consumption of drugs and/or herbal preparations capable of inducing hepatic enzyme
metabolism (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or
St. John's Wort) or enzyme-inhibiting agents (e.g., cimetidine) or similar drugs
within 28 days (or 5 half-lives of inducing/inhibiting agent, whichever is longer) of
Screening
- Major surgery within 180 days (6 months) of the start of this study
- Subjects who have experienced a significant upper or lower respiratory tract infection
within the 42 days (6 weeks) prior to Screening
- Subjects with significant history of respiratory, renal, hepatic, cardiovascular
(including history of systemic hypertension requiring therapy), metabolic,
neurological, hematological, gastrointestinal, cerebrovascular, or other significant
medical illness or disorder which, in the judgment of the investigator, may interfere
with the study or require treatment which may affect the evaluation of the safety of
the study drug
- Subjects with elevated liver enzyme concentrations at Screening and at Day -1
- Hemoglobin level < 130 g/L taken at Screening and at Day -1
- Serum potassium > 5 mEq/L taken at Screening and at Day -1
- Poor venous access
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2010
Query!
Sample size
Target
24
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Nucleus Network, Ltd. - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and tolerability of repeated doses of
GS-9411 in healthy volunteers. GS-9411 is a sodium channel inhibitor, that may restore airway
hydration and mucociliary clearance in the lung.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00999531
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Peter Hodsman, MD
Query!
Address
0
0
Nucleus Network Ltd
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00999531
Download to PDF